Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro does not stop you drinking alcohol, but many people find their desire for it changes significantly once treatment begins. That shift is real, reported widely by people on tirzepatide, and worth understanding before your first dose. Mounjaro is a prescription-only medicine requiring clinical assessment; a prescriber decides whether it is right for you. What follows is an honest account of what the evidence and clinical experience actually show — without the myths.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the most common misunderstanding around this topic, and it deserves a clear answer first. Mounjaro does not contain disulfiram, naltrexone, or any other agent that interferes with how your body processes alcohol. There is no pharmacological mechanism in tirzepatide that physically prevents you from drinking or causes an adverse reaction when alcohol is consumed.
The confusion probably stems from the fact that many people on tirzepatide genuinely do drink less, not because they are forced to, but because their relationship with food and drink seems to shift. That is a very different thing. The change is real; the cause is not a hidden blocker. Understanding the distinction matters, because treating the reduced desire as a rule rather than a side effect of appetite change can lead to poor decisions if tolerance builds back without warning.
For a broader look at alcohol and tirzepatide, the drinking on tirzepatide page covers the clinical picture in full.
Tirzepatide works by activating two gut-hormone receptors: GIP and GLP-1. One of the effects is slowing gastric emptying, which means food (and drink) moves out of your stomach more slowly. The medicine also appears to reduce general reward-seeking behaviour tied to appetite. Several people taking GLP-1 medicines have reported that cravings which had nothing to do with hunger (for alcohol, for cigarettes, for snacks eaten out of habit) seemed quieter while on treatment.
This is not a licensed indication. Tirzepatide is approved in the UK for weight management and type 2 diabetes, as the Mounjaro overview explains. Reduced alcohol craving is an observed pattern, not a guaranteed effect and not a reason to start treatment. The NHS notes appetite-related changes as part of how GLP-1 medicines work, and researchers are actively studying reward pathways as a secondary area of interest.
The practical consequence is straightforward: if you notice you are drinking less than usual, that is likely a genuine physiological response worth paying attention to, not something to override.
Because tirzepatide slows gastric emptying, alcohol may reach your bloodstream more slowly than it used to. That sounds like it might reduce the effect, but the reverse risk is more relevant: the delayed absorption makes it harder to judge how much you have consumed before the full effect lands. People sometimes drink more in that window and find it hits harder later.
On top of that, alcohol can worsen the gastrointestinal side effects that are already the most common complaint with tirzepatide (nausea, reflux and stomach discomfort) particularly in the early weeks of treatment or after a dose increase. The cost and treatment page gives context on how treatment is structured, but the side-effect picture is one reason clinical oversight matters throughout.
Heavy or regular alcohol use can also raise the risk of pancreatitis, which is separately flagged as a known but infrequent serious risk of GLP-1 medicines. In January 2026, the MHRA issued a Drug Safety Update specifically drawing attention to acute pancreatitis with GLP-1 receptor agonists: severe, persistent stomach pain that spreads to the back (with or without vomiting) requires urgent medical attention. Alcohol adds to that risk, not away from it.
The drinking on Mounjaro page goes into the safety picture in detail, and drinking wine on Mounjaro addresses some of the more specific questions people search for. For those thinking about hydration more broadly, staying well hydrated on treatment is worth reading separately, it is more relevant than many people expect.
If you drink occasionally and moderately, Mounjaro is not incompatible with that. Most prescribers do not require total abstinence. What they will want to know is your honest drinking pattern, because it feeds into the clinical picture alongside your weight, medical history and any other medicines you take. That assessment happens before any prescription is issued.
The can you drink on Mounjaro page answers the direct question about what is and is not advisable. And if you notice your usual tolerance has dropped during treatment (a commonly reported experience) treat that as useful information rather than an invitation to test it. The drinking while on Mounjaro page covers the practical guidance worth keeping in mind.
Mounjaro arrives in a plain, unbranded box via DPD tracked delivery, and the pen itself is a pre-filled KwikPen you keep in the fridge. The clinical part (a real prescriber reviewing your consultation the same day) happens before any of that, and your prescriber is the right person to talk through your specific situation with, including your alcohol habits. The frequently asked questions page covers common queries, and our clinical team is here if you want to understand the process first. For factual information on how tirzepatide works and its side-effect profile, the NHS medicines page for tirzepatide is a reliable starting point, as is the MHRA Yellow Card scheme for reporting any side effects you experience.
If you would like to discuss whether Mounjaro is suitable for you, speak to our prescribers through a free consultation at the treatments page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.